ZURPAVY
LIVE

Serial Number

98513412

Owner

Celgene Corporation

Attorney

Xiomara Triana

Filing Date

Apr 22, 2024

Add to watchlist:

No watchlists yet
View on USPTO

ZURPAVY Trademark

Serial Number: 98513412

ZURPAVY is a trademark filed by Celgene Corporation on April 22, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Celgene Corporation (883 trademarks)

7 Powder Horn Drive
Warren, NJ 07059

Entity Type: 03

Trademark Details

Filing Date

April 22, 2024

Registration Date

Not Registered

Published for Opposition

March 18, 2025

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; cytokine inhibitory drugs being pharmaceutical preparations for the treatment of cancer; anticoagulants; Pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy for the treatment of cancer; Pharmaceutical and biological preparations for human use, namely, stem cells for medical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; diagnostic preparations for human use for medical purposes; radiopharmaceutical preparations for human use in the nature of imaging and detection agents for diagnosing and monitoring cancer; biological preparations for human use in the nature of radio-isotope markers for therapeutic or diagnostic use; Pharmaceutical preparations for human use for the treatment of cystic fibrosis

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 6, 2026 EXRA
SOU EXTENSION 2 GRANTED
May 6, 2026 EX2G
SOU EXTENSION 2 FILED
May 6, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
May 6, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 5, 2025 EXRA
SOU EXTENSION 1 GRANTED
Nov 4, 2025 EX1G
SOU EXTENSION 1 FILED
Nov 4, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 4, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 13, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 18, 2025 NPUB
PUBLISHED FOR OPPOSITION
Mar 18, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 12, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 20, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 7, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 7, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 7, 2025 TROA
NOTICE OF REVIVAL - E-MAILED
Jan 7, 2025 NREV
PETITION TO REVIVE-GRANTED
Jan 7, 2025 PETG
TEAS PETITION TO REVIVE RECEIVED
Jan 7, 2025 PROA
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jan 3, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jan 3, 2025 ABN2
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 10, 2024 NWOS
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 12, 2024 GNRN
NON-FINAL ACTION E-MAILED
Sep 12, 2024 GNRT
NON-FINAL ACTION WRITTEN
Sep 12, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 12, 2024 DOCK
NEW APPLICATION ENTERED
Apr 22, 2024 NWAP